What is HC Wainwright's Forecast for AKRO Q1 Earnings?

Key Points

• HC Wainwright predicts Akero Therapeutics will report a Q1 2026 earnings loss of ($0.96) per share, maintaining a "Buy" rating with a price target of $72.00.
• The consensus estimate for Akero's full-year earnings is a loss of ($3.99) per share, with projections for consecutive quarterly losses through Q4 2026.
• Eight analysts currently rate Akero Therapeutics' stock as a "Buy," with a consensus target price of $81.14, despite the stock recently trading down 3.5%.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Akero Therapeutics in a report released on Thursday, September 4th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.96) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $72.00 price objective on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics' Q2 2026 earnings at ($0.99) EPS, Q3 2026 earnings at ($1.02) EPS and Q4 2026 earnings at ($1.04) EPS.

Other analysts also recently issued reports about the stock. Citigroup dropped their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Bank of America boosted their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. TD Cowen initiated coverage on shares of Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating and a $76.00 target price on the stock. Wall Street Zen upgraded shares of Akero Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Finally, Cowen initiated coverage on shares of Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating on the stock. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Akero Therapeutics has an average rating of "Buy" and an average target price of $81.14.

Akero Therapeutics Price Performance

Shares of AKRO stock traded down $1.64 during midday trading on Friday, reaching $42.99. 535,021 shares of the company were exchanged, compared to its average volume of 1,366,686. Akero Therapeutics has a 12 month low of $21.34 and a 12 month high of $58.40. The company has a market cap of $3.44 billion, a P/E ratio of -21.49 and a beta of -0.24. The company's 50 day moving average price is $49.30 and its two-hundred day moving average price is $46.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.66 and a current ratio of 12.66.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.11. During the same quarter in the prior year, the company earned ($0.81) EPS.

Institutional Trading of Akero Therapeutics

Several large investors have recently added to or reduced their stakes in AKRO. Holocene Advisors LP bought a new stake in Akero Therapeutics in the second quarter worth approximately $57,396,000. Bank of America Corp DE grew its position in Akero Therapeutics by 406.7% in the second quarter. Bank of America Corp DE now owns 1,320,461 shares of the company's stock worth $70,460,000 after acquiring an additional 1,059,860 shares in the last quarter. RTW Investments LP grew its position in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after acquiring an additional 940,388 shares in the last quarter. Bellevue Group AG grew its position in Akero Therapeutics by 58.7% in the second quarter. Bellevue Group AG now owns 1,985,272 shares of the company's stock worth $105,934,000 after acquiring an additional 734,606 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Akero Therapeutics in the fourth quarter worth $18,059,000.

Insider Activity

In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of the business's stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $51.16, for a total value of $1,534,800.00. Following the completion of the sale, the chief executive officer directly owned 520,757 shares of the company's stock, valued at $26,641,928.12. The trade was a 5.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Jonathan Young sold 12,500 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $47.79, for a total transaction of $597,375.00. Following the completion of the sale, the chief operating officer directly owned 197,484 shares of the company's stock, valued at $9,437,760.36. This represents a 5.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 148,192 shares of company stock valued at $7,484,661 in the last three months. 7.07% of the stock is currently owned by insiders.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.